logo
  

Veracyte: Data Suggests Cancer Risk Classification Using Clinical Factors Alone May Be Suboptimal

Veracyte, Inc. (VCYT) said new data show that the company's Decipher Prostate
Genomic Classifier may help identify African American men with early, localized
prostate cancer who are most likely to harbor more aggressive disease. The data from the VANDAAM Phase 2 study suggest that the genomic test may offer a robust improvement over clinical factors alone in risk-stratifying prostate cancer among African American men, which may help reduce disparities in prostate cancer outcomes.

"This study demonstrates that prostate cancer risk classification using clinical factors alone may be suboptimal and may underestimate African American men's risk of harboring aggressive disease," said Elai Davicioni, Veracyte's medical director, Urology.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lenoir, North Carolina -based Exela Pharma Sciences, LLC has expanded its recall of Sodium Bicarbonate Injection due to vial breakage to include more lots, the U.S. Food and Drug Administration said. The product is used for treatment of metabolic acidosis and is packaged in a 50 mL glass vial, 20 vials per carton. Elon Musk, who recently took Twitter Inc. private in a $44-billion deal, accused Apple Inc. of threatening to block the social media platform from its app store without giving the reason. In a series of tweets on Monday, the Tesla founder and CEO also said the tech giant had stopped advertising on Twitter, and that it was pressuring the firm over content moderation demands. Payments platform Paysafe has inked a partnership deal with Richard Branson's Virgin Voyages to enable travelers to speedily and securely make online payments for reserving next cruise booking. Paysafe's travel solution will also help mitigate all payment risks for travelers.
RELATED NEWS
Follow RTT